Sutro Biopharma KOL Event

Virtual, December 3, 2020

General Agenda

KOL Speakers:

Wendel Naumann, MD 
Director, Minimally Invasive Surgery in Gynecologic Oncology
Professor, Department of Ob/Gyn at Atrium Health, Levine Cancer Institute

Lainie P. Martin, MD
Leader, Gynecology/Oncology Program
Associate Professor of Medicine, Hospital at University of Pennsylvania

RSVP for Event / Log Back in Presenter Access

Additional menu options can be found in the menu bar on the left or at the top.

Sutro Biopharma [STRO] $876 MM MCap
FolR&al­pha;-tar­get­ing ADC (STRO-002) Phase 1, an­ti­ci­pat­ed pre­lim­i­nary da­ta in ovarian can­cer and EOP1/2 FDA meet­ing in 2H21. CD74-tar­get­ing ADC (STRO-001) Phase 1 dose-ex­pan­sion to be ini­ti­at­ed in 2H21. Pre-clin­i­cal da­ta and IND pro­jec­tions for STRO-003 in gen­er­al can­cer an­ti­ci­pat­ed for 2H21. BMS col­lab­o­ra­tion for CC-99712 (BC­MA-tar­get­ing ADC) grant­ed or­phan drug desig­na­tion in Fe­bruary 21. IND-en­abling tox ini­ti­at­ed for Mer­ck col­lab­o­ra­tion on a cy­tokine deri­va­tive pro­gram. [more in­for­ma­tion]